Forced out of retirement by these trades

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available

Bruce Eaton Biography and Net Worth

EVP of Editas Medicine

Prior to joining Editas Medicine, Dr. Eaton was Founder and CEO of i2 Pharmaceuticals. Before founding i2, Dr. Eaton was Chief Operating Officer of SomaLogic, where he was responsible for operations, business development, and corporate strategy. Earlier in his career, Dr. Eaton served as Vice President of NexaGen and was on the integration team responsible for the merger with Vestar and the formation of NexStar Pharmaceuticals, where he built and led the groups responsible for good manufacturing practice (GMP) synthesis and analytics for an investigational new drug (IND) application for the Age-Related Macular Degeneration (AMD) drug Macugen™ (Bausch + Laumb). At NexStar, Dr. Eaton was also responsible for alliance management of all research and process development efforts to support the liposomal delivery technology related to the drug Ambisome™ (Gilead Sciences, Inc., and Astellas Pharma, Inc.).

Dr. Eaton received his Ph.D. in chemistry from the University of California at Berkeley. He earned B.S. degrees in chemistry and biology from the University of Oregon. He is a member of the Board of Directors of the Colorado Bioscience Association.

What is Bruce Eaton's net worth?: The estimated net worth of Bruce Eaton is at least $90,497.11 as of December 5th, 2023. Eaton owns 74,791 shares of Editas Medicine stock worth more than $90,497 as of December 25th. This net worth approximation does not reflect any other investments that Eaton may own. Learn More about Bruce Eaton's net worth.
How do I contact Bruce Eaton?: The corporate mailing address for Eaton and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at [email protected]. Learn More on Bruce Eaton's contact information.
Has Bruce Eaton been buying or selling shares of Editas Medicine?: Bruce Eaton has not been actively trading shares of Editas Medicine during the last ninety days. Most recently, Bruce Eaton sold 103 shares of the business's stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $10.90, for a transaction totalling $1,122.70. Following the completion of the sale, the executive vice president now directly owns 74,791 shares of the company's stock, valued at $815,221.90. Learn More on Bruce Eaton's trading history.
Who are Editas Medicine's active insiders?: Editas Medicine's insider roster includes Katrine Bosley (CEO), Bruce Eaton (EVP), Lisa Michaels (EVP), James Mullen (CEO), and Michelle Robertson (CFO). Learn More on Editas Medicine's active insiders.
Are insiders buying or selling shares of Editas Medicine?: During the last year, Editas Medicine insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $253,800.00. During the last year, insiders at the sold shares 10 times. They sold a total of 133,590 shares worth more than $1,104,930.91. The most recent insider tranaction occured on December, 3rd when CEO Gilmore Neil O'neill sold 1,618 shares worth more than $3,365.44. Insiders at Editas Medicine own 1.9% of the company. Learn More about insider trades at Editas Medicine.
Information on this page was last updated on 12/3/2024.

Bruce Eaton Insider Trading History at Editas Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2023	Sell	103	$10.90	$1,122.70	74,791
11/7/2023	Sell	139	$8.40	$1,167.60	75,589
9/6/2023	Sell	103	$8.82	$908.46	75,728
8/11/2023	Sell	702	$8.59	$6,030.18	75,831
8/8/2023	Sell	141	$8.39	$1,182.99	76,533
6/5/2023	Sell	105	$9.50	$997.50	76,674
5/11/2023	Sell	668	$9.87	$6,593.16	76,779
5/9/2023	Sell	135	$9.51	$1,283.85	77,447
3/3/2023	Sell	101	$8.89	$897.89	77,582
2/7/2023	Sell	346	$11.10	$3,840.60	64,290
11/8/2022	Sell	289	$11.02	$3,184.78	64,738
6/3/2022	Sell	1,123	$11.54	$12,959.42	65,421
5/9/2022	Sell	297	$13.11	$3,893.67	66,544
4/1/2022	Sell	1,258	$19.64	$24,707.12	66,841
3/3/2022	Sell	403	$17.33	$6,983.99
2/8/2022	Sell	302	$17.63	$5,324.26
11/9/2021	Sell	287	$40.61	$11,655.07

Bruce Eaton Buying and Selling Activity at Editas Medicine

Editas Medicine Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $1.21

$1.20

$1.26

50 Day Range

MA: $2.50

$1.21

$3.76

2 Week Range

Now: $1.21

$1.20

$11.58

Volume

1,580,551 shs

Average Volume

2,050,229 shs

Market Capitalization

$99.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87